Biota completes new flu trial
Thursday, 31 July, 2008
Biota Holdings [ASX: BTA] has completed the Phase II trials of its influenza treatment CS-8958, with Phase III trials set to commence later this year.
CS-8958 is a long-acting neuraminidase inhibitor [LANI], and is co-owned by Daiichi-Sankyo.
Several hundred flu patients participated in the double-blind trial, which was conducted to the standards of the Japanese Pharmaceuticals and Medical Devices Agency.
The trial revealed that one dose of CS-8958 produced results indistinguishable from 75mg of oseltamivir administered twice daily for five days.
Exclusive colostrum intake may reduce risk of food allergies
Newborns who are exclusively fed colostrum in the first 72 hours following birth are five times...
Sunscreen and supplements can lower your vitamin D levels
People who use SPF50+ sunscreen daily are more likely to be vitamin D deficient, while taking...
Low-dose drug prevents diabetes progression in young people
A low dose of the immunomodulatory drug anti-thymocyte globulin (ATG) appears safe and effective...
